Xiangyu Medical Establishes Sun-BCI Lab and Unveils BCI Product Portfolio in IPO Filing

China Securities News (Wang Lu) -- On March 13, Sunnyou (688626) disclosed its investor relations activity record. Sunnyou introduced that currently, the company has established the Sun-BCI Lab for brain-computer interface and created four major product systems, covering EEG acquisition devices (Sun Link), brain-controlled products (Sun Brain), life-scenario products (Sun Live), and self-developed algorithms (Sun Dip). Among them, the EEG machines, EEG acquisition devices, and mental health-related products are expected to obtain medical device registration certificates in the second half of the year.

The company will also focus on the development of equipment in areas such as neurofeedback, cognitive screening, sleep disorder intervention, and neonatal EEG monitoring. At the same time, it will promote the intelligent iteration and upgrading of existing motion rehabilitation products and cognitive products, leading the new future of smart healthcare. In addition, the company will actively participate in the drafting and publication of brain-computer interface industry standards and group standards, jointly improving China's brain-computer interface industry standard system.

Sunnyou Medical revealed that the company will generate a structured model through in-depth cooperation with research institutions and clinical organizations to obtain high-quality, desensitized, and real patient case files and examination data. Combined with a private rehabilitation domain knowledge graph, the large model will undergo secondary training to build a vertical domain model. The company will ensure data compliance through data encryption and security measures. Its full-category products, industry-academia-research cooperation, and extensive customer coverage have formed a strong competitive advantage.

Sunnyou Medical stated that in 2024, the company's operating revenue will remain basically the same as the previous year; due to the increase in R&D personnel salaries and related expenses, the company's net profit will decrease. In 2025, facing opportunities and challenges, the company will firmly focus on clinical needs, continuously promote and optimize specialized disease and hospital-wide clinical rehabilitation integrated solutions. While refining its areas of strength, it will launch more products and solutions that meet clinical needs and the demands of medical care, rehabilitation, and elderly care markets in areas such as mental health, brain-computer interfaces, and rehabilitation robotics; increase marketing efforts for exports, out-of-hospital, and home-based services, and actively develop a second growth curve.